Daily Newsletter

21 September 2023

Daily Newsletter

21 September 2023

SpyBiotech submits CTA to UK MHRA for HCMV vaccine

The first patient is anticipated to receive the first dose of the vaccine later this year.

RanjithKumar Dharma September 21 2023

SpyBiotech has submitted a clinical trial application (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the assessment of the SPYVLP01 vaccine targeting human cytomegalovirus (HCMV).

SPYVLP01 is designed to combat HCMV by leveraging the Hepatitis B virus-like-particle platform technology.

The assessment of various formulations of SpyBiotech's HCMV vaccine is the primary objective of the Phase I clinical study.

The trial intends to enrol around 120 participants.

The first participant is set to receive the first dose later this year and clinical data is anticipated to be revealed in the first half of next year.

SpyBiotech president and chief scientific officer Sumi Biswas said: “Submission of our clinical trial application to evaluate SPYVLP01 marks important progress in the fight against the HCMV virus, a leading infectious cause of congenital abnormalities.

“We believe in the potential of the SpyVLP vaccine platform technology. While our lead program is focused on HCMV, our vaccine technology can be applied to generate vaccines against a wide range of pathogens and therapeutic indications.”

The company’s new SpyVLP vaccine platform is based on a protein ‘superglue’ technology that binds antigens to vaccine delivery platforms for reducing delivery risk and improving efficacy and immunogenicity.

SpyBiotech CEO Mark Leuchtenberger said: “The MHRA trial application is a strong next step in the development of our cost-effective and highly scalable vaccine technology.

“There is a great need for medical progress against HCMV. There is no currently approved vaccine against this betaherpesvirus that can cause lifelong infection in humans.”

Multiple Myeloma (MM) pipeline dominated by CAR-T cells

The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close